China Pharmaceutical Group Corporation, or Sinopharm, is a large pharmaceutical and healthcare conglomerate under the direct supervision of the State Council, specializing in the production and distribution of preventive and therapeutic, diagnostic and care products, as well as related research and development businesses. The group has an extensive business footprint with more than 1,500 subsidiaries, including well-known listed companies such as Sinopharm, Sinopharm, Sinopharm Consolidated, Tiantan Bio, Modern Pharmaceuticals, and China National Traditional Chinese Medicine.
GMP is committed to building five core platforms: first, an integrated operation platform for modern logistics and distribution to optimize the supply chain of pharmaceutical products; second, an integrated scientific and technological innovation platform for industry-university-research to promote cutting-edge advances in pharmaceutical research and development; third, a nationwide network of pharmaceutical retail chains to provide consumers with a convenient channel for purchasing medicines; fourth, a nationwide narcotic distribution network to ensure the safe supply of medicines; and fifth, a nationwide marketing and cold chain distribution network of biological products. national marketing and cold chain distribution network for biological products to ensure the quality and efficiency of biological products. In addition, the Group covers medical equipment distribution, pharmaceutical scientific research and engineering design, overseas business expansion, pharmaceutical exhibition and media, as well as the overall development of medical and healthcare industry, forming an innovation-driven modernized enterprise group with the pharmaceutical and healthcare industry at its core.